The clinical effect of sacubitril valsartan combined with dapagliflozin in heart failure with reduced ejection fraction and non-diabetes patients

Jianli WANG; Lin ZHOU; Xiaoling XIAO; Yong XU; Aiqun MA

Return

The clinical effect of sacubitril valsartan combined with dapagliflozin in heart failure with reduced ejection fraction and non-diabetes patients

VernacularTitle:沙库巴曲缬沙坦联合达格列净对射血分数减低型心衰不伴糖尿病患者的疗效
Author: Jianli WANG ¹ ; Lin ZHOU ¹ ; Xiaoling XIAO ¹ ; Yong XU ¹ ; Aiqun MA ²
Author Information

1. Department of Cardiovascular Medicine, the Sixth People’s Hospital of Chengdu, Chengdu 610051
2. Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
Publication Type:Journal Article
Keywords: sacubitril valsartan; dapagliflozin; heart failure with reduced ejection fraction (HFrEF); diabetes
From: Journal of Xi'an Jiaotong University(Medical Sciences) 2023;44(3):415-420
CountryChina
Language:Chinese
Abstract: 【Objective】 To observe the clinical effect of combination therapy of sacubitril valsartan and dapagliflozin in heart failure with reduced ejection fraction (HFrEF) and non-diabetes patients. 【Methods】 This study involved 96 patients with HFrEF and non-diabetes. The patients were randomly divided into control group (50 cases) and observation group (46 cases). On the basis of routine treatment, the control group was treated with sacubitril valsartan, while the observation group was treated with sacubitril valsartan and dapagliflozin. After 1-month and 6-month treatment, we monitored blood pressure, N-terminal pro brain natriuretic peptide (NT-proBNP), high sensitivity troponin T (cTnT), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDd), left atrial diameter (LAD), left ventricular posterior wall thickness (LVPW), Minnesota soda heart failure life quality score (MLHFQ), the incidence of rehospitalization and death, and major adverse cardiovascular events (MACE) in the two groups. 【Results】 After 6 months, systolic blood pressure, cTnT, NT-proBNP, LVEDd, LVPW, and LAD of the observation group were significantly decreased compared with the control group (P<0.05), the LVEF value was significantly increased (P<0.05), and the MLHFQ and MACE incidence were significantly decreased (P<0.05). However, the two groups did not significantly differ in FBG or HbA1c (P>0.05). 【Conclusion】 The combination treatment of sacubitril valsartan and dapagliflozin on HFrEF and non-diabetes patients can significantly improve cardiac function, inhibit myocardial remodeling, reduce the incidence of MACE, and improve the prognosis.